FreeTheAI

SS Innovations Responds to FDA Request for SSi Mantra Robotic System

BullishMedium impact
SSII$2.54 −0.20%

SS Innovations International (NASDAQ:SSII) has submitted its official response to the U.S. Food and Drug Administration regarding additional information requested for its SSi Mantra surgical robotic system. The submission supports the company's 510(k) application for gallbladder removal procedures, known as cholecystectomy. The updated filing includes final results from an expanded human clinical and human factors validation study, alongside data from an August 2026 bridging study conducted at Hospital Internacional de Colombia.

The filing represents a key regulatory milestone for the developer of surgical robotics as it seeks to enter the American healthcare market. The SSi Mantra system features modular robotic arms, an ergonomic command center, and a 3D 4K display designed to make robotic surgery more accessible and affordable. Completing the requested study data allows federal regulators to proceed with evaluating the system's safety and efficacy for commercial launch in the United States.

The company expects federal regulators to finish reviewing the response and overall 510(k) submission in the first quarter of 2027. Investors will be tracking the regulatory decision, as approval would grant market clearance for initial surgical procedures and advance the firm's broader international expansion efforts. In trading today, shares of SS Innovations International were down 1.96% at $2.50.

Key points

  • SS Innovations International (NASDAQ:SSII) submitted its response to an FDA request for additional information on October 5, 2026.
  • The response supports a 510(k) clearance application for gallbladder removal procedures using the SSi Mantra robotic system.
  • The submission included final data from expanded clinical studies and an August 2026 bridging study in Colombia.
  • SS Innovations International expects the FDA to conclude its review during the first quarter of 2027.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What did SS Innovations submit to the FDA?

SS Innovations submitted a response to the FDA's request for additional information regarding its 510(k) application for the SSi Mantra surgical robotic system. The response included final clinical and human factors validation study data for gallbladder removal procedures.

When does SS Innovations expect FDA review completion for SSi Mantra?

The company anticipates that the FDA will complete its review of the response and 510(k) submission during the first quarter of 2027.

What is the SSi Mantra surgical robotic system?

The SSi Mantra is a modular, multi-arm surgical robotic system equipped with an open-faced command center, 3D 4K visualization, and over 40 types of endo-surgical instruments designed for various surgical specialties.